Xie J, Saburulla N, Chen S, Wong S, Yap Z, Zhang L, et al. Evaluation of Carbazeran 4-Oxidation and O 6-Benzylguanine 8-Oxidation as Catalytic Markers of Human Aldehyde Oxidase: Impact of Cytosolic Contamination of Liver Microsomes. Drug Metab Dispos. 2019;47:26-37 pubmed publisher

Uehara S, Uno Y, Okamoto E, Inoue T, Sasaki E, Yamazaki H. Molecular Cloning and Characterization of Marmoset Aldehyde Oxidase. Drug Metab Dispos. 2017;45:883-886 pubmed publisher

Wilkinson D, Southall R, Li M, Wright L, Corfield L, Heeley T, et al. Minipig and Human Metabolism of Aldehyde Oxidase Substrates: In Vitro-In Vivo Comparisons. AAPS J. 2017;19:1163-1174 pubmed publisher

Miyamoto M, Iwasaki S, Chisaki I, Nakagawa S, Amano N, Hirabayashi H. Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver. Xenobiotica. 2017;47:1052-1063 pubmed publisher

Ballard T, Wang S, Cox L, Moen M, Krzyzewski S, Ukairo O, et al. Application of a Micropatterned Cocultured Hepatocyte System To Predict Preclinical and Human-Specific Drug Metabolism. Drug Metab Dispos. 2016;44:172-9 pubmed publisher

Sodhi J, Wong S, Kirkpatrick D, Liu L, Khojasteh S, Hop C, et al. A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834. Drug Metab Dispos. 2015;43:908-15 pubmed publisher

Manevski N, Balavenkatraman K, Bertschi B, Swart P, Walles M, Camenisch G, et al. Aldehyde oxidase activity in fresh human skin. Drug Metab Dispos. 2014;42:2049-57 pubmed publisher

Sharma R, Strelevitz T, Gao H, Clark A, Schildknegt K, Obach R, et al. Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs. Drug Metab Dispos. 2012;40:625-34 pubmed publisher

Critchley D, Rance D, Beedham C. Biotransformation of carbazeran in guinea pig: effect of hydralazine pretreatment. Xenobiotica. 1994;24:37-47 pubmed

Taylor C, Baird J, Blackburn K, Cambridge D, Constantine J, Ghaly M, et al. Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure. Am Heart J. 1981;102:515-32 pubmed

Hillis W, Been M. Phosphodiesterase inhibitors: haemodynamic effects related to the treatment of cardiac failure. Eur Heart J. 1982;3 Suppl D:97-101 pubmed

Kaye B, Offerman J, Reid J, Elliott H, Hillis W. A species difference in the presystemic metabolism of carbazeran in dog and man. Xenobiotica. 1984;14:935-45 pubmed

el Allaf D, D Orio V, Carlier J. The new inotropic phosphodiesterase inhibitors. Arch Int Physiol Biochim. 1984;92:S69-79 pubmed

Kaye B, Rance D, Waring L. Oxidative metabolism of carbazeran in vitro by liver cytosol of baboon and man. Xenobiotica. 1985;15:237-42 pubmed

Price B, Pyne N, Houslay M. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue. Biochem Pharmacol. 1987;36:4047-54 pubmed

Shahid M, Rodger I. Chronotropic and inotropic actions of amrinone, carbazeran and isobutylmethyl xanthine: role of phosphodiesterase inhibition. Br J Pharmacol. 1989;98:291-301 pubmed